By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Phosphoproteomics firm Activiomics today announced a technology agreement with biopharmaceutical company UCB to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.
Researchers report that what scents someone picks up can reflect their complement of immune genes.
The New York Times examines ethics and China's push to lead biomedical research.
At her blog, Sally Rockey dives into National Institutes of Health funding data.